Brain Cancer

Tovorafenib generated durable drug holiday responses in pediatric patients with BRAF-altered relapsed/refractory low-grade glioma.

IGV-001, an autologous cell immunotherapy, demonstrated an acceptable safety profile in patients with newly diagnosed glioblastoma.

The NMPA has approved belzutifan for von Hippel-Lindau disease in RCC, CNS hemangioblastomas, or pNETs not requiring immediate surgery.

The FDA has granted orphan drug designation to the herpes simplex virus type 1 oncolytic virus MB-108 for the management of malignant glioma.

In case you missed any, read a recap of every episode of OncLive On Air that aired in October 2024.

The FDA has accepted and granted priority review to the new drug application for the glioma imaging agent TLX101-CDx.

LP-184 has received fast track designation from the FDA for the treatment of patients with glioblastoma.

LMP744 has been granted orphan drug designation by the FDA for the treatment of patients with glioma.

An update on PFS and OS data from the phase 1 MAGIC-G1 study of MTX110 in recurrent glioblastoma has been released.

The FDA has granted rare pediatric disease designation to LP-184 in malignant rhabdoid tumors, rhabdomyosarcoma, and hepatoblastoma.

The phase 2 trial of the gamma-delta T-cell therapy INB-400 plus temozolomide in patients with newly diagnosed GBM has suspended enrollment.

This list features a snapshot of key August FDA oncology decisions, efforts to integrate health equity into guideline development, and more.

Seema Nagpal, MD, discusses the significance of the FDA approval of vorasidenib for adult and pediatric patients with IDH1/2-mutant glioma.

Here is your snapshot of all therapeutic options that the FDA approved in August 2024 and their clinical implications.

An NDA has been submitted to the FDA for TLX101-CDx for the characterization of progressive or recurrent glioma in adult and pediatric patients.

Opaganib has received orphan drug designation from the FDA for use in patients with neuroblastoma.

The FDA has awarded rare pediatric disease designation and orphan drug designation to INV724 for the treatment of neuroblastoma.

Rhenium obisbemeda proved feasible and safe for patients with leptomeningeal metastases in an interim analysis of the phase 1 ReSPECT-LM trial.

The FDA has approved vorasidenib for grade 2 astrocytoma or oligodendroglioma with a susceptible IDH1 or IDH2 mutation.

The European Medicines Agency has approved Avzivi, a biosimilar referencing bevacizumab.

Paxalisib improved OS over SOC in patients with newly diagnosed glioblastoma and unmethylated MGMT promotor status.

Nathalie Albert, MD, explains that amino acid PET scans can be valuable tools in monitoring disease progression and assessing a patient's response to treatment, while also exploring the optimal timing for utilizing these scans in the overall management of brain tumors.

Nathalie Albert, MD, delves into advanced MRI techniques such as perfusion imaging, functional MRI, MR spectroscopy, and DEMARCATE, while also exploring the role of PET imaging, particularly those utilizing glucose and amino acid tracers in neuroimaging.

The European Medicines Agency’s Committee for Medicinal Products for Human Use adopted a positive opinion for Avzivi, a monoclonal antibody referencing bevacizumab.

AGuIX has been granted FDA fast track designation in malignant gliomas and glioblastoma.

Experts engage in a comprehensive discussion on conventional imaging techniques, evaluating the strengths and limitations of CT and MRI scans, particularly in delineating tumor borders and distinguishing between tumors and the surrounding central nervous system tissue.

Medical experts discuss the use of various neuroimaging techniques, such as MRIs, CT scans, and PET scans, emphasizing that due to limitations of MRI it is frequently combined with other modalities to obtain more comprehensive information.

Sarah ES Leary, MD, MS, details the significance of the FDA-approval of tovorafenib for patients with relapsed or refractory BRAF-positive pediatric low-grade glioma.

James Knight, MD, discusses a case study of a patient with brain metastases from prostate cancer and the importance of multidisciplinary, comprehensive care.

Hideho Okada, MD, PhD, discusses cancer immunoprevention through the lens of vaccine approaches in patients with low-grade glioma.